Souhaitez-vous accéder aux communiqués récents ?

Trial analysis published in JNCI predicts residual cancer burden from baseline H&E slides using 4D Path's fully automated, treatment predictive platform

Positive feedback reinforces Silexion’s trajectory toward its planned Phase 2/3 trial initiation in Q2 2026 Company plans to complete regulatory submissions to the Israeli Ministry of Health by the...

Grand Cayman, Cayman Islands, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced...

Successful completion of two-species toxicology studies confirms no systemic organ toxicity, advancing the Company towards its  planned regulatory submissions to Israel and Germany Company remains on...

Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026 New preclinical data demonstrated SIL204’s exceptional efficacy across multiple human cancer cell...

Dublin, Nov. 07, 2025 (GLOBE NEWSWIRE) -- The "Cancer Gene Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ...

Dublin, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The "Precision Oncology Market Report 2025" report has been added to ResearchAndMarkets.com's offering.The precision oncology market size has grown rapidly...

Dublin, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The "Gastric Cancer Market - A Global and Regional Analysis: Focus on Treatment Type, End User, and Region - Analysis and Forecast, 2025-2035" has been...

Chicago, IL, Nov. 04, 2025 (GLOBE NEWSWIRE) -- PersonaDx, a precision diagnostic oncology company transforming how metastatic cancers are classified and treated, announced today that its co-founder...

Three posters to be presented featuring pre-clinical data of potential best-in-class FGFR3 selective inhibitor, SMARCA2 selective inhibitor, and P53 Y220C reactivatorCandidates for FGFR3 and SMARCA2...